More on Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Low-dose vs. standard-dose alteplase for acute ischemic stroke: a retrospective cohort study of safety and efficacy in an Iranian population.BMC neurology · 2025
   Article
2. Low-dose versus standard-dose alteplase for intravenous thrombolysis in patients with acute ischemic stroke in Iran: Results from the safe implementation of treatments in stroke registry.Current journal of neurology · 2021
   Article
3. Therapeutic effects of alteplase intravenous thrombolysis on different types of acute cerebral infarction: a controlled randomized analysis.American journal of translational research · 2021
   Article
4. A Bayesian Network Model for Predicting Post-stroke Outcomes With Available Risk Factors.Frontiers in neurology · 2018
   Article

Corrections and comments

• Erratum for
  Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.